Frequently asked questions about CELEBREX® (celecoxib)

Why should I consider CELEBREX?
- Just one 200-mg CELEBREX can provide 24-hour relief for many with arthritis pain and inflammation.*
- In clinical studies with osteoarthritis patients, CELEBREX was proven to improve daily physical function so moving is easier.
- In fact, CELEBREX improves pain, stiffness, and physical function.
- CELEBREX is not a narcotic.
- CELEBREX can be taken with or without food so you don’t have to plan around it.

Can I take low-dose aspirin with CELEBREX?
- Yes, if you are taking low-dose aspirin for your heart and need an NSAID pain reliever, CELEBREX can be used because it doesn’t interfere with aspirin’s antiplatelet effect.
- However, taking low-dose aspirin may not reduce the cardiovascular risk associated with NSAID use. With any NSAID, including CELEBREX, patients also taking aspirin are at an increased risk for stomach bleeding and ulcers. CELEBREX is not a substitute for aspirin in preventing heart attack or stroke.

*Individual results may vary; this dosing is for osteoarthritis.

What about stomach upset?
- You may be interested to know, in clinical studies, a lower percentage of patients taking CELEBREX reported stomach upset (including indigestion, abdominal pain, and nausea) versus prescription ibuprofen and naproxen.
- However, all NSAIDs, including CELEBREX, increase the chance of stomach and intestine problems, such as bleeding and ulcers, which can occur without warning and may cause death.

Are there cardiovascular risks associated with CELEBREX?
- The FDA requires all prescription NSAIDs, including CELEBREX, ibuprofen, naproxen, and meloxicam, to have the same cardiovascular warning.
- They may all increase the chance of heart attack or stroke, which can lead to death. This chance increases if you have heart disease or risk factors for it such as high blood pressure or when NSAIDs are taken for long periods.

How should I take CELEBREX?
- It’s important to take CELEBREX as your doctor prescribes. If you experience side effects, speak to your doctor immediately. Your doctor can help determine the correct dosage and length of treatment for you.

To learn more about CELEBREX, visit celebrex.com or call 1-888-CELEBREX.

Indications:
CELEBREX is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.

Important Safety Information:
Like all prescription NSAIDs, CELEBREX may increase the chance of heart attack or stroke that can lead to death. This chance increases if you have heart disease or risk factors for it, such as high blood pressure or when NSAIDs are taken for long periods.

CELEBREX should not be used right before or after certain heart surgeries.

Serious skin reactions, or stomach and intestine problems such as bleeding and ulcers, can occur without warning and may cause death. Patients taking aspirin and the elderly are at increased risk for stomach bleeding and ulcers.

Tell your doctor if you have:
- A history of ulcers or bleeding in the stomach or intestines
- High blood pressure or heart failure
- Kidney or liver problems

CELEBREX should not be taken in late pregnancy.

Do not take CELEBREX if you’ve had an asthma attack, hives, or other allergic reactions to aspirin, any other NSAID medicine, or certain drugs called sulfonamides.

Life threatening allergic reactions can occur with CELEBREX. Get help right away if you’ve had swelling of the face or throat or trouble breathing.

Prescription CELEBREX should be used exactly as prescribed at the lowest dose possible and for the shortest time needed.

Please see the accompanying full Prescribing Information, including the Medication Guide, for important safety information.
HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use Celebrex safely and effectively. See full prescribing information for Celebrex.

Celebrex® (celecoxib) capsules

Initial U.S. Approval: 1998

WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISKS

See full prescribing information for complete boxed warning

Cardiovascular Risk

• Celebrex, may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. All NSAIDs may have a similar risk. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (5.1, 14.6)
• Celebrex is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. (4, 5.1)

Gastrointestinal Risk

• NSAIDs, including Celebrex, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal (GI) events. (5.4)

INDICATIONS AND USAGE

Celebrex is a nonsteroidal anti-inflammatory drug indicated for:

• Osteoarthritis (OA) (1.1)
• Rheumatoid Arthritis (RA) (1.2)
• Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older (1.3)
• Ankylosing Spondylitis (AS) (1.4)
• Acute Pain (AP) (1.5)
• Primary Dysmenorrhea (PD) (1.6)

DOSAGE AND ADMINISTRATION

Use lowest effective dose for the shortest duration consistent with treatment goals for the individual patient. (1, 5.1, 5.4)

• OA: 200 mg once daily or 100 mg twice daily (2.1, 14.1)
• RA: 100 to 200 mg twice daily (2.2, 14.2)
• JRA: 50 mg twice daily in patients 10-25 kg, 100 mg twice daily in patients more than 25 kg (2.3, 14.3)
• AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit (2.4, 14.4)
• AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed (2.5, 14.5)

Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers, (2.6, 8.4, 8.8, 12.3).

DOSAGE FORMS AND STRENGTHS

Capsules: 50 mg, 100 mg, 200 mg and 400 mg (3)

ADVERSE REACTIONS

Most common adverse reactions in arthritis trials (>2% and >placebo): abdominal pain, diarrhea, dyspepsia, flatulence, peripheral edema, accidental injury, dizziness, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, rash (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

DRUG INTERACTIONS

• Concomitant use of Celebrex and warfarin may result in increased risk of bleeding complications. (7.1)
• Concomitant use of Celebrex increases lithium plasma levels. (7.2)
• Concomitant use of Celebrex may reduce the antihypertensive effect of ACE Inhibitors and angiotensin II antagonists. Concomitant use of Celebrex with ACE-Inhibitors in elderly or volume depleted or renally compromised patients may result in deterioration of renal function, including acute renal failure. (7.4)
• Use caution with drugs known to inhibit P450 2C9 or metabolized by 2D6 due to the potential for increased plasma levels (2.6, 8.4, 8.8, 12.3)

USE IN SPECIFIC POPULATIONS

• Pregnancy Category C prior to 30 weeks gestation; Category D starting at 30 weeks gestation (5.9, 8.1, 17.8)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide

Revised: April 2012
FULL PRESCRIBING INFORMATION: CONTENTS*

BOXED WARNING

1. INDICATIONS AND USAGE
   1.1 Osteoarthritis
   1.2 Rheumatoid Arthritis
   1.3 Juvenile Rheumatoid Arthritis
   1.4 Ankylosing Spondylitis
   1.5 Acute Pain
   1.6 Primary Dysmenorrhea

2. DOSAGE AND ADMINISTRATION
   2.1 Osteoarthritis
   2.2 Rheumatoid Arthritis
   2.3 Juvenile Rheumatoid Arthritis
   2.4 Ankylosing Spondylitis
   2.5 Management of Acute Pain and Treatment of Primary Dysmenorrhea
   2.6 Special Populations

3. DOSAGE FORMS AND STRENGTHS

4. CONTRAINDICATIONS

5. WARNINGS AND PRECAUTIONS
   5.1 Cardiovascular Thrombotic Events
   5.2 Hypertension
   5.3 Congestive Heart Failure and Edema
   5.4 Gastrointestinal (GI) Effects
   5.5 Hepatic Effects
   5.6 Renal Effects
   5.7 Anaphylactoid Reactions
   5.8 Skin Reactions
   5.9 Pregnancy
   5.10 Corticosteroid Treatment
   5.11 Hematological Effects
   5.12 Disseminated Intravascular Coagulation (DIC)
   5.13 Preexisting Asthma
   5.14 Laboratory Tests
   5.15 Inflammation
   5.16 Concomitant NSAID Use

6. ADVERSE REACTIONS
   6.1 Pre-marketing Controlled Arthritis Trials
   6.2 The Celecoxib Long-Term Arthritis Safety Study
   6.3 Juvenile Rheumatoid Arthritis Study
   6.4 Other Pre-Approval Studies
   6.5 The APC and PreSAP Trials

7. DRUG INTERACTIONS
   7.1 Warfarin
   7.2 Lithium
   7.3 Aspirin
   7.4 ACE-Inhibitors and Angiotensin II Antagonists
   7.5 Fluconazole
   7.6 Furosemide
   7.7 Methotrexate
   7.8 Concomitant NSAID Use

8. USE IN SPECIFIC POPULATIONS
   8.1 Pregnancy
   8.2 Labor and Delivery
   8.3 Nursing Mothers
   8.4 Pediatric Use
   8.5 Geriatric Use
   8.6 Hepatic Insufficiency
   8.7 Renal Insufficiency
   8.8 Poor Metabolizers of CYP2C9 Substrates

10. OVERDOSAGE

11. DESCRIPTION

12. CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action
    12.2 Pharmacodynamics
    12.3 Pharmacokinetics
    12.5 Pharmacogenomics

13. NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
    13.2 Animal Toxicology

14. CLINICAL STUDIES
    14.1 Osteoarthritis
    14.2 Rheumatoid Arthritis
    14.3 Juvenile Rheumatoid Arthritis
    14.4 Ankylosing Spondylitis
    14.5 Analgesia, Including Primary Dysmenorrhea
    14.6 Special Studies

16. HOW SUPPLIED/STORAGE AND HANDLING

17. PATIENT COUNSELING INFORMATION
    17.1 Medication Guide
    17.2 Cardiovascular Effects
    17.3 Gastrointestinal Effects
    17.4 Hepatic Effects
    17.5 Adverse Skin Reactions
    17.6 Weight Gain and Edema
    17.7 Anaphylactoid Reactions
    17.8 Effects During Pregnancy
    17.9 Preexisting Asthma

* Sections or subsections omitted from the Full Prescribing Information are not listed.
2.6 Special Populations

1.4 Ankylosing Spondylitis (AS)

2.2 Rheumatoid Arthritis

1.3 Juvenile Rheumatoid Arthritis (JRA)

2. Dosing and Administration

1.5 Acute Pain (AP)

1. INDICATIONS AND USE

NSAIDs, including CELEBREX, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (3.4)

1. Osteoarthritis (OA)

CELEBREX is indicated for relief of the signs and symptoms of OA [see Clinical Studies (14.1)].

1. Rheumatoid Arthritis (RA)

CELEBREX is indicated for relief of the signs and symptoms of RA [see Clinical Studies (14.2)].

1. Juvenile Rheumatoid Arthritis (JRA)

CELEBREX is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3)].

1. Ankylosing Spondylitis (AS)

CELEBREX is indicated for relief of the signs and symptoms of AS [see Clinical Studies (14.4)].

1. Acute Pain (AP)

CELEBREX is indicated for the management of AP in adults [see Clinical Studies (14.5)].

1. Primary Dysmenorrhea (PD)

CELEBREX is indicated for the treatment of PD [see Clinical Studies (14.5)].

2. DOSAGE AND ADMINISTRATION

Use lowest effective dose for the shortest duration consistent with treatment goals for the individual patient.

These doses can be given without regard to timing of meals.

2.1 Osteoarthritis

For relief of the signs and symptoms of OA the recommended oral dose is 200 mg per day administered as a single dose or as 100 mg twice daily.

2.2 Rheumatoid Arthritis

For relief of the signs and symptoms of RA the recommended oral dose is 100 to 200 mg twice daily.

2.3 Juvenile Rheumatoid Arthritis

For the relief of the signs and symptoms of JRA the recommended oral dose for pediatric patients (age 2 years and older) is based on weight. For patients ≥10 kg to ≤25 kg the recommended dose is 50 mg twice daily. For patients >25 kg the recommended dose is 100 mg twice daily.

For patients who have difficulty swallowing capsules, the contents of a CELEBREX capsule can be added to applesauce. The entire capsule contents are carefully emptied onto a level teaspoon of cool or room temperature applesauce and ingested immediately with water. The sprinkled capsule contents on applesauce are stable for up to 6 hours under refrigerated conditions (2°C to 8°C /35°F to 45°F).

2.4 Ankylosing Spondylitis

For the management of the signs and symptoms of AS, the recommended dose of CELEBREX is 200 mg daily in single (once per day) or divided (twice per day) doses. If no effect is observed after 6 weeks, a trial of 400 mg daily may be worthwhile. If no effect is observed after 6 weeks on 400 mg daily, a response is not likely and consideration should be given to alternate treatment options.

2.5 Management of Acute Pain and Treatment of Primary Dysmenorrhea

The recommended dose of CELEBREX is 400 mg initially, followed by an additional 200 mg dose if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily as needed.

2. Special Populations

Hepatic insufficiency: The daily recommended dose of CELEBREX capsules in patients with moderate hepatic impairment (Child-Pugh Class B) should be reduced by 50%. The use of CELEBREX in patients with severe hepatic impairment is not recommended [see Warnings and Precautions (5.5), Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

Poor Metabolizers of CYP2C9 Substrates: Patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin, phenytoin) should be administered celecoxib with caution. Consider starting treatment at half the lowest recommended dose in poor metabolizers (i.e. CYP2C9*3/*3). Consider using alternative management in JRA patients who are poor metabolizers. [See Use in Specific Populations (8.8), and Clinical Pharmacology (12.5)].

3. DOSAGE FORMS AND STRENGTHS

Capsules: 50 mg, 100 mg, 200 mg and 400 mg

4. CONTRAINDICATIONS

CELEBREX is contraindicated:

• In patients with known hypersensitivity to celecoxib, aspirin, or other NSAIDs.

• In patients who have demonstrated allergic-type reactions to sulfonamides.

• In patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe anaphylactic reactions to NSAIDs, some of them fatal, have been reported in such patients [see Warnings and Precautions (5.7, 5.13)].

• For the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery [see Warnings and Precautions (5.1)].

5. WARNINGS AND PRECAUTIONS

5.1 Cardiovascular Thrombotic Events

Chronic use of CELEBREX may cause an increased risk of serious adverse cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. In the APC (Adenoma Prevention with Celecoxib) trial, the hazard ratio for the composite endpoint of cardiovascular death, MI, or stroke was 2.4 (95% CI 1.4 – 8.5) for CELEBREX 400 mg twice daily and 2.8 (95% CI 1.1 – 7.2) with Celebrex 200 mg twice daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects), respectively, compared to 0.9% (6/679 subjects) with placebo treatment. The increases in both celecoxib dose groups versus placebo-treated patients were mainly due to an increased incidence of myocardial infarction [see Clinical Studies (14.6)].

All NSAIDs, both COX-2 selective and non-selective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with CELEBREX, the lowest effective dose should be used for the shortest duration consistent with individual patient treatment goals. Physicians and patients should remain alert for the development of such events. Patients should be advised to discontinue CELEBREX therapy and promptly initiate additional evaluation and treatment if a serious CV adverse event is suspected. For high-risk patients, alternate therapies that do not involve NSAIDs should be considered.

5.2 Hypertension

As with all NSAIDs, CELEBREX can lead to the onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including CELEBREX, should be used with caution in patients with hypertension. Blood pressure should be monitored closely during the initiation of therapy with CELEBREX and throughout the course of therapy. The rates of hypertension from the CLASS trial in the CELEBREX, ibuprofen and diclofenac-treated patients were 2.4%, 4.2% and 2.5%, respectively [see Clinical Studies (14.6)].

5.3 Congestive Heart Failure and Edema

Fluid retention and edema have been observed in some patients taking NSAIDs, including CELEBREX [see Adverse Reactions (6.1)]. In the CLASS study [see Clinical Studies (14.6)], the Kaplan-Meier cumulative rates at 9 months of peripheral edema in patients on CELEBREX 400 mg twice daily (4-fold and 2-fold the recommended OA and RA doses, respectively), ibuprofen 800 mg three times daily and diclofenac 75 mg twice daily were 4.5%, 6.9% and 4.7%, respectively. CELEBREX should be used with caution in patients with fluid retention or heart failure.

5.4 Gastrointestinal (GI) Effects

Risk of GI Ulceration, Bleeding, and Perforation

NSAIDs, including CELEBREX, can cause serious gastrointestinal events including bleeding, ulceration, and perforation of the stomach, small intestine or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Complicated and symptomatic ulcer rates were 0.78% at nine months for all patients in the CLASS trial, and 2.19% for the subgroup on low-dose ASA. Patients 65 years of age and older had an incidence of 1.40% at nine months, 3.06% when also taking ASA [see Clinical Studies (14.6)]. With longer duration of use of NSAIDs, there is a trend for increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk. NSAIDs should be prescribed with extreme caution in patients with a prior history of ulcer disease or gastrointestinal bleeding. Patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to patients with neither of these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID use, history of smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore special care should be taken in treating this population.

To minimize the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest duration consistent with individual patient treatment goals. Physicians and patients should remain alert for signs and symptoms of GI ulceration and bleeding during CELEBREX therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. For high-risk patients, alternate therapies that do not involve NSAIDs should be considered.
5.5 Hepatic Effects
Borderline elevations of one or more liver-associated enzymes may occur in up to 15% of patients taking NSAIDs, and notable elevations of ALT or AST (approximately 3 or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure (some with fatal outcome) have been reported with NSAIDs, including CLEVEREX [see Adverse Reactions (6.1)]. In controlled clinical trials of CLEVEREX, the incidence of borderline elevations (greater than or equal to 1.2 times and less than 3 times the upper limit of normal) of liver associated enzymes was 6% for CLEVEREX and 5% for placebo, and approximately 0.2% of patients taking CLEVEREX and 0.3% of patients taking placebo had notable elevations of ALT and AST.

A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be monitored carefully for evidence of the development of a more severe hepatic reaction while on therapy with CLEVEREX. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), CLEVEREX should be discontinued.

5.6 Renal Effects
Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, ACE-inhibitors, angiotensin II receptor antagonists, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. Clinical trials with CLEVEREX have shown renal effects similar to those observed with comparator NSAIDs.

No information is available from controlled clinical studies regarding the use of CLEVEREX in patients with advanced renal disease. Therefore, treatment with CLEVEREX is not recommended in these patients with advanced renal disease. If CLEVEREX therapy must be initiated, close monitoring of the patient’s renal function is advisable.

5.7 Anaphylactoid Reactions
As with NSAIDs in general, anaphylactoid reactions have occurred in patients without known prior exposure to CLEVEREX. In post-marketing experience, rare cases of anaphylactic reactions and angioedema have been reported in patients receiving CLEVEREX. CLEVEREX should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs [see Contraindications (4), Warnings and Precautions (5.7)]. Emergency help should be sought in cases where an anaphylactoid reaction occurs.

5.8 Skin Reactions
CLEVEREX is a sulfonamide and can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events can occur without warning and in patients without prior known sulfa allergy. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.

5.9 Pregnancy
In late pregnancy, starting at 30 weeks gestation, CLEVEREX should be avoided because it may cause premature closure of the ductus arteriosus [see Use in Specific Populations (8.1)].

5.10 Corticosteroid Treatment
CLEVEREX cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to exacerbation of corticosteroid-responsive illness. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.

5.11 Hematological Effects
Anemia is sometimes seen in patients receiving CLEVEREX. In controlled clinical trials the incidence of anemia was 0.6% with CLEVEREX and 0.4% with placebo. Patients on long-term treatment with CLEVEREX should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia or blood loss. CLEVEREX does not generally increase platelet count, prothrombin time (PTT), or partial thromboplastin time, and does not inhibit platelet aggregation at indicated dosages [see Clinical Pharmacology (12.2)].

5.12 Disseminated Intravascular Coagulation (DIC)
CLEVEREX should be used only with caution in pediatric patients with systemic onset JRA due to the risk of disseminated intravascular coagulation.

5.13 Preexisting Asthma
Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm, which can be fatal. Since cross-reactivity, including bronchospasm, between aspirin and other non-steroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, CLEVEREX should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.

5.14 Laboratory Tests
Because serious GI tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of GI bleeding. Patients on long-term treatment with NSAIDs should have a CBC and a chemistry profile checked periodically. If abnormal liver tests or renal tests persist or worsen, CLEVEREX should be discontinued. In controlled clinical trials, elevated BUN occurred more frequently in patients receiving CLEVEREX compared with patients on placebo. This laboratory abnormality was also seen in patients who received comparator NSAIDs in these studies. The clinical significance of this abnormality has not been established.

5.15 Inflammation
The pharmacological activity of CLEVEREX in reducing inflammation, and possibly fever, may diminish the utility of these diagnostic signs in detecting infectious complications of presumed noninfectious, painful conditions.

5.16 Concomitant NSAID Use
The concomitant use of CLEVEREX with any dose of a non-aspirin NSAID should be avoided due to the potential for increased risk of adverse reactions.

6. ADVERSE REACTIONS
Of the CLEVEREX-treated patients in the pre-marketing controlled clinical trials, approximately 4,250 were patients with OA, approximately 2,100 were patients with RA, and approximately 1,050 were patients with post-surgical pain. More than 8,500 patients received a total daily dose of CLEVEREX of 200 mg (100 mg twice daily or 200 mg once daily) or more, including more than 400 treated at 800 mg (400 mg twice daily). Approximately 3,900 patients received CLEVEREX at these doses for 6 months or more; approximately 2,300 of these have received it for 1 year or more and 124 of these have received it for 2 years or more.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and cannot reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

6.1 Pre-marketing Controlled Arthritis Trials

| Body as a whole | CLEVEREX Placebo NAP DCF IBU |
|----------------|-----------------|-----------------|-----------------|-----------------|
| *Back Pain* | 2.8% | 3.6% | 2.2% | 2.6% | 0.9% |
| *Peripheral Edema* | 2.1% | 1.1% | 2.1% | 1.0% | 3.5% |
| *Injury-Accidental* | 2.9% | 2.3% | 3.0% | 2.6% | 3.2% |

| Central, Peripheral Nervous system | CLEVEREX Placebo NAP DCF IBU |
|-----------------------------------|-----------------|-----------------|-----------------|-----------------|
| *Dizziness* | 2.0% | 1.7% | 2.6% | 1.3% | 2.3% |
| *Headache* | 15.8% | 20.2% | 14.5% | 15.5% | 15.4% |

| Psychiatric | CLEVEREX Placebo NAP DCF IBU |
|-------------|-----------------|-----------------|-----------------|-----------------|
| *Insomnia* | 2.3% | 2.3% | 2.9% | 1.3% | 1.4% |

| Respiratory | CLEVEREX Placebo NAP DCF IBU |
|-------------|-----------------|-----------------|-----------------|-----------------|
| *Pharyngitis* | 2.3% | 1.1% | 1.7% | 1.6% | 2.6% |
| *Rhinitis* | 2.0% | 1.3% | 2.4% | 2.3% | 0.6% |
| *Sinusitis* | 5.0% | 4.3% | 4.0% | 5.4% | 5.8% |

| Upper Respiratory Infection | CLEVEREX Placebo NAP DCF IBU |
|-----------------------------|-----------------|-----------------|-----------------|-----------------|
| *Bronchitis* | 8.1% | 6.7% | 9.9% | 9.8% | 9.9% |

| Skin | CLEVEREX Placebo NAP DCF IBU |
|-----|-----------------|-----------------|-----------------|-----------------|
| *Rash* | 2.2% | 2.1% | 2.1% | 1.3% | 1.2% |

CBX = CLEVEREX 100 – 200 mg twice daily or 200 mg once daily;
NAP = Naproxxen 500 mg twice daily;
DCF = Diclofenac 75 mg twice daily;
IBU = Ibuprofen 800 mg three times daily.

In placebo- or active-controlled clinical trials, the discontinuation rate due to adverse events was 7.1% for patients receiving CLEVEREX and 6.1% for patients receiving placebo. Among the most common reasons for discontinuation due to adverse events in the CLEVEREX treatment groups were dyspepsia and abdominal pain (cited as reasons for discontinuation in 0.8% and 0.7% of CLEVEREX patients, respectively). Among patients receiving placebo, 0.5% discontinued due to dyspepsia and 0.6% withdrew due to abdominal pain.

The following adverse reactions occurred in 0.1 - 1.9% of patients treated with CLEVEREX (100 - 200 mg twice daily or 200 mg once daily):

**Gastrointestinal:**
- Constipation, diverticulitis, dysphagia, eructation, esophagitis, gastri
tis, gastroenteritis, gastroesophageal reflux, hemorrhoids, hiatal hernia,
melela, dry mouth, stomatitis, tenesmus, vomiting

**Cardiovascular:**
- Aggravated hypertension, angiina pectoris, coronary artery disorder,
myocardial infarction

**General:**
- Allergy aggravated, allergic reaction, chest pain, cyst NOS, edema
generalized, face edema, fatigue, fever, hot flushes, influenza-like
symptoms, pain, peripheral pain

**Central, peripheral nervous system:**
- Leg cramps, hypertonia, hypotetasis, migraine, paresthesia, vertigo
The following serious adverse events (causality not evaluated) occurred in <0.1% of patients (cases reported only in post-marketing experience are indicated in italics):

### Cardiovascular:
- Syncope, congestive heart failure, ventricular fibrillation, pulmonary embolism, cerebrovascular accident, peripheral gangrene, thromboembolitis, vasculitis, deep venous thrombosis

### Gastrointestinal:
- Intestinal obstruction, intestinal perforation, gastrointestinal bleeding, colitis with bleeding, esophageal perforation, pancreatitis, ileus

### Liver and biliary:
- Cholelithiasis, hepatitis, jaundice, liver failure

### Hematologic:
- Thrombocytopenia, agranulocytosis, aplastic anemia, pancytopenia, leukopenia

### Skin:
- Erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS, or hypersensitivity syndrome)

### General:
- Sepsis, sudden death, anaphylactoid reaction, angioedema

#### 6.2 The Celecoxib Long-Term Arthritis Safety Study

##### Hematological Events:
The incidence of clinically significant decreases in hemoglobin (>2 g/dL) was lower in patients on CEBREX 400 mg twice daily (0.5%) compared to patients on either diclofenac 75 mg twice daily (1.3%) or ibuprofen 800 mg three times daily 1.9%. The lower incidence of events with CEBREX was maintained with or without ASA use (see Clinical Pharmacology (7.1)).

##### Withdrawals/Serious Adverse Events:
Kaplan-Meier cumulative rates at 9 months for withdrawals due to adverse events for CEBREX, diclofenac and ibuprofen were 24%, 29%, and 26%, respectively. Rates for serious adverse events (i.e., causing hospitalization or felt to be life-threatening or otherwise medically significant), regardless of causality, were not different across treatment groups (8%, 7%, and 8%, respectively).

#### 6.3 Juvenile Rheumatoid Arthritis Study
In a 12-week, double-blind, active-controlled study, 242 JRA patients 2 years to 17 years of age were treated with celecoxib or naproxen; 77 JRA patients were treated with celecoxib 3 mg/kg BID, 82 patients were treated with celecoxib 6 mg/kg BID, and 83 patients were treated with naproxen 7.5 mg/kg BID. The most commonly occurring (<5%) adverse events in celecoxib treated patients were headache, fever (pyrexia), upper abdominal pain, cough, nasopharyngitis, abdominal pain, nausea, arthralgia, diarrhea and vomiting. The most commonly occurring (<5%) adverse experiences for naproxen-treated patients were headache, nausea, vomiting, fever, upper abdominal pain, diarrhea, cough, abdominal pain, and dizziness (Table 2). Compared with naproxen, celecoxib at doses of 3 and 6 mg/kg BID had no observable deleterious effect on growth and development when observed over the course of the 12-week double-blind study. There was no substantial difference in the number of clinical exacerbations of uveitis or systemic features of JRA among treatment groups.

In a 12-week, open-label extension of the double-blind study described above, 202 JRA patients were treated with celecoxib 6 mg/kg BID. The incidence of adverse events was similar to that observed during the double-blind study; no unexpected adverse events of clinical importance emerged.
7. Drug Interactions

General: Celecoxib metabolism is predominantly mediated via cytochrome P450 (CYP) CYP2C9 in the liver. Co-administration of celecoxib with drugs that are known to inhibit CYP2C9, such as Warfarin, should be done with caution. Significant interactions may occur when celecoxib is administered together with drugs that inhibit CYP2C9.

In vitro studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. Therefore, there is a potential for an in vivo drug interaction with drugs that are metabolized by CYP2D6.

7.1 Warfarin

Anticoagulant activity should be monitored, particularly in the first few days, after initiating or changing celecoxib therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications. The effect of celecoxib on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily 2-5 mg doses of warfarin. In these subjects, celecoxib did not alter the anticoagulant effect of warfarin as determined by prothrombin time. However, in post-marketing experience, serious bleeding events, some of which were fatal, have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving celecoxib concurrently with warfarin.

7.2 Lithium

In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg twice daily with celecoxib 200 mg twice daily as compared to subjects receiving lithium alone. Patients on lithium treatment should be closely monitored when celecoxib is introduced or withdrawn.

7.3 Aspirin

Celecoxib can be used with low-dose aspirin. However, concomitant administration of aspirin with celecoxib increases the rate of GI ulceration or other complications, compared to use of celecoxib alone [see Warnings and Precautions (5.1, 5.4) and Clinical Studies (14.6)]. Because of its lack of platelet effects, celecoxib is not a substitute for aspirin for cardiovascular prophylaxis [see Clinical Pharmacology (12.2)].

7.4 ACE-inhibitors and Angiotensin II Antagonists

Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors and angiotensin II antagonists. This interaction should be given consideration in patients taking celecoxib concomitantly with ACE-inhibitors and angiotensin II antagonists [see Clinical Pharmacology (12.2)].

In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, may result in deterioration of renal function, including possible acute renal failure. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

7.5 Fluconazole

Concomitant administration of fluconazole at 200 mg once daily resulted in a two-fold increase in celecoxib plasma concentration. This increase is due to the inhibition of celecoxib metabolism via P450 CYP2C9 by fluconazole [see Clinical Pharmacology (12.3)]. Celecoxib should be introduced at the lowest recommended dose in patients receiving fluconazole.

7.6 Fusidocin

Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of fusidocin and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis.

7.7 Methotrexate

In an interaction study of rheumatoid arthritis patients taking methotrexate, celecoxib did not have an effect on the pharmacokinetics of methotrexate [see Clinical Pharmacology (12.3)].

7.8 Concomitant NSAID Use

The concomitant use of celecoxib with any dose of a non-aspirin NSAID should be avoided due to the potential for increased risk of adverse reactions.

8. USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C. Pregnancy category D from 30 weeks of gestation onward.

Teratogenic effects: Celecoxib at oral doses ≥150 mg/kg/day (approximately 2-fold human exposure at 400 mg/day) caused an increased incidence of ventricular septal defects, a rare event, and fetal alterations, such as ribs fused, sternebrae fused and sternebrae misshapen when rabbits were treated throughout organogenesis. A dose-dependent increase in diaphragmatic hernias was observed when rats were given celecoxib at oral doses ≥30 mg/kg/day (approximately 6-fold human exposure based on the AUC24h at 200 mg twice daily) throughout organogenesis. There are no studies in pregnant women. Celecoxib should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic effects: Celecoxib produces pre-implantation and post-implantation losses and reduced embryo/fetal survival in rats at oral doses ≥50 mg/kg/day (approximately 6-fold human exposure based on the AUC24h at 200 mg twice daily). These changes are expected with inhibition of prostaglandin synthesis and are not the result of permanent alteration of female reproductive function, nor are they expected at clinical exposures. No studies have been conducted to evaluate the effect of celecoxib on the closure of the ductus arteriosus in humans. Therefore, use of Celecoxib during the third trimester of pregnancy should be avoided.
11. DESCRIPTION

Celebrex (celecoxib) is chemically designated as 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide and is a diaryl-substituted pyrazole. The empirical formula is C_{14}H_{13}F_{3}N_{2}O_{3}S, and the molecular weight is 361.38. The chemical structure is as follows:

Celebrex oral capsules contain either 50 mg, 100 mg, 200 mg or 400 mg of celecoxib, together with inactive ingredients including: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.

12. CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Celebrex is a nonsteroidal anti-inflammatory drug that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of Celebrex is believed to be due to inhibition of prostanoid synthase, primarily via inhibition of cyclooxygenase-2 (COX-2), and at therapeutic concentrations in humans, Celebrex does not inhibit the cyclooxygenase-1 (COX-1) isoenzyme. In animal colunumor models, Celebrex reduced the incidence and multiplicity of tumors.

12.2 Pharmacodynamics

Platelets: In clinical trials using normal volunteers, Celebrex at single doses up to 800 mg and multiple doses of 600 mg twice daily for up to 7 days duration (higher than recommended therapeutic doses) had no effect on reduction of platelet aggregation or increase in bleeding time. Because of its lack of platelet effects, Celebrex is not a substitute for aspirin for cardiovascular prophylaxis. It is not known if there are any effects of Celebrex on platelets that may contribute to the increased risk of serious cardiovascular thrombotic adverse events associated with the use of Celebrex.

Fluid Retention: Inhibition of PGE2 synthesis may lead to sodium and water retention through increased reabsorption in the renal medullary thick ascending loop of Henle and perhaps other segments of the distal nephron. In the collecting ducts, PGE2 appears to inhibit proximal reabsorption by countering the action of antidiuretic hormone.

12.3 Pharmacokinetics

Absorption: Peak plasma levels of celecoxib occur approximately 3 hours after an oral dose. Under fasting conditions, both peak plasma levels (C\text{max}) and area under the curve (AUC) are roughly dose-proportional up to 200 mg BID; at higher doses there are less than proportional increases in C\text{max} and AUC (see Food Effects). Absolute bioavailability studies have not been conducted. With multiple dosing, steady-state conditions are reached on or before Day 5. The pharmacokinetic parameters of celecoxib in a group of healthy subjects are shown in Table 3.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>C\text{max}, ng/mL</td>
<td>705 (38)</td>
</tr>
<tr>
<td>T\text{max}, hr</td>
<td>2.8 (31)</td>
</tr>
<tr>
<td>Effective T\text{1/2}, hr</td>
<td>11.2 (31)</td>
</tr>
<tr>
<td>V\text{ss}/F, L</td>
<td>429 (34)</td>
</tr>
<tr>
<td>CL/F, L/hr</td>
<td>27.7 (28)</td>
</tr>
</tbody>
</table>

Subjects under fasting conditions (n=36, 19-52 yrs.)

Food Effects: When Celebrex capsules were taken with a high fat meal, peak plasma levels were delayed for about 1 to 2 hours with an increase in total absorption (AUC) of perhaps other segments of the distal nephron. In the collecting ducts, PGE2 appears to inhibit reabsorption by countering the action of antidiuretic hormone.

Celebrex does not inhibit the cyclooxygenase-1 (COX-1) isoenzyme. In animal colon tumor models, Celebrex reduced the incidence and multiplicity of tumors.

In vitro studies indicate that celecoxib binds primarily to albumin (85-90%) and, to a lesser extent, to other plasma proteins. Approximately 57% of the dose was excreted in the feces and 27% was unchanged drug recovered in the urine and feces. Following a single oral dose of radio-labeled drug, approximately 57% of the dose was excreted in the feces and 27% was excreted into the urine. The primary metabolite in both urine and feces was the carboxylic acid metabolite (73% of dose) with low amounts of the glucuronide also appearing in the urine. It appears that the low solubility of the drug prolongs the absorption process making terminal half-life (t\text{1/2}) determinations more variable. The effective half-life is approximately 11 hours under fasted conditions. The apparent plasma clearance (CL/F) is about 500 mL/min.

Geriatric: At steady state, elderly subjects (over 65 years old) had a 40%-higher C\text{max} and a 50%-higher AUC compared to the young subjects. In elderly female subjects, C\text{max} and AUC are higher than those for elderly males, but these increases are predominantly due to lower body weight in elderly females. Dose adjustment in the elderly is not generally necessary. However, for patients of less than 50 kg in body weight, initiate therapy at the lowest recommended dose (see Dosage and Administration (2.6) and Use in Specific Populations (8.5)).

Pediatric: The steady state pharmacokinetics of celecoxib administered as an investigational oral suspension was evaluated in 152 JRA patients 2 years to 17 years of age weighing ≥10 kg with pauciarticular or polyarticular course JRA and in patients with systemic onset JRA. Population pharmacokinetic analysis indicated that the oral clearance (unadjusted for body weight) of celecoxib increases less than proportionally to increasing weight, with 10 kg and 25 kg patients predicted to have 40% and 24% lower clearance, respectively, compared with a 70 kg adult RA patient. Twice-daily administration of 50 mg capsules to JRA patients weighing ≥12 to ≤25 kg and 100 mg capsules to JRA patients weighing ≥25 kg should achieve plasma concentrations similar to those observed in a clinical trial that demonstrated the non-inferiority of celecoxib to naproxen 7.5 mg/kg twice daily (see Dosage and Administration (2.3)). Celecoxib has not been studied in JRA patients under the age of 2 years, in patients with body weight less than 10 kg (22 lbs.), or beyond 24 weeks.

Race: Meta-analysis of pharmacokinetic studies has suggested an approximately 40% higher AUC of celecoxib in Blacks compared to Caucasians. The cause and clinical significance of this finding is unknown.

Hepatic Insufficiency: A pharmacokinetic study in subjects with mild (Child-Pugh Class A) and moderate (Child-Pugh Class B) hepatic impairment has shown that steady-state celecoxib AUC is increased about 40% and 180%, respectively, above that seen in healthy control subjects. Therefore, the daily recommended dose of Celebrex capsules should be reduced by approximately 50% in patients with moderate (Child-Pugh Class B) hepatic impairment. Patients with severe hepatic impairment (Child-Pugh Class C) have not been studied. The use of Celebrex in patients with severe hepatic impairment is not recommended (see Dosage and Administration (2.6) and Use in Specific Populations (8.6)).

Renal Insufficiency: In a cross-study comparison, celecoxib AUC was approximately 40% lower in patients with chronic renal insufficiency (GFR 35-60 mL/min) than in those seen in subjects with normal renal function. No significant relationship was found between GFR and celecoxib clearance. Patients with severe renal insufficiency have not been studied. Similar to other NSAIDs, Celebrex is not recommended in patients with severe renal insufficiency (see Warnings and Precautions (5.6)).

Drugs Interactions:

In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9 2C19 or 3A4.

In vivo studies have shown the following:

Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg twice daily with Celebrex 200 mg twice daily as compared to subjects receiving lithium alone (see Drug Interactions (7.2)).

Fluconazole: Concomitant administration of fluconazole at 200 mg once daily resulted in a two-fold increase in celecoxib plasma concentration. This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see Drug Interactions (7.5)).

Other Drugs: The effects of celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketonozol, metrotrexate, see Drug Interactions (7.7)., phenytoin, and tobitusamide have been studied in vivo and clinically important interactions have not been found.

12.5 Pharmacogenomics

CYP2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*2 and CYP2C9*3 polymorphisms. Limited data from published reports that included a total of 8 subjects with the homozygous CYP2C9*3/*3 genotype showed celecoxib systemic levels that were 3- to 7-fold higher in these subjects compared to subjects with CYP2C9*1/*1 or *1/*3 genotypes. The pharmacokinetics of celecoxib have not been evaluated in subjects with other CYP2C9 polymorphisms, such as *2, *5, *6, *9 and *11. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3% to 1.0% in various ethnic groups. (see Dosage and Administration (2.6), Use in Specific Populations (8.8)).

13. NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Celecoxib was not carcinogenic in rats given oral doses up to 200 mg/kg for males and 10 mg/kg for females (approximately 2- to 4-fold the human exposure as measured by the AUC\text{0-24} at 200 mg twice daily) or in mice given oral doses up to 25 mg/kg for males and 50 mg/kg for females (approximately equal to human exposure as measured by the AUC\text{0-24} at 200 mg twice daily) for two years.

Celecoxib was not mutagenic in an Ames test and a mutation assay in Chinese hamster ovary (CHO) cells, nor clastogenic in a chromosome aberration assay in CHO cells and an in vivo micronucleus test in rat bone marrow.

Celecoxib did not impair male and female fertility in rats at oral doses up to 600 mg/kg/day (approximately 11-fold human exposure at 200 mg twice daily based on the AUC\text{0-24} at 200 mg twice daily).
14.3 Animal Toxicology

CELEBREX has demonstrated significant reduction in joint tenderness/pain and joint swelling compared to placebo. CELEBREX was evaluated for treatment of the signs and symptoms of OA in the knee and hip of adults in placebo- and active-controlled clinical trials of up to 12 weeks duration. In patients with OA, treatment with CELEBREX 100 mg twice daily or 200 mg once daily resulted in improvement in WOMAC (Western Ontario and McMaster Universities) osteoarthritis index, a composite of pain, stiffness, and functional measures in OA. In three 12-week studies of pain accompanying OA flare, CELEBREX doses of 100 mg twice daily and 200 mg twice daily provided significant reduction of pain within 24-48 hours of initial dosing. At doses of 100 mg twice daily or 200 mg twice daily, the response rate of CELEBREX was shown to be similar to that of naproxen 500 mg twice daily. Doses of 200 mg twice daily provided no additional benefit above that seen with 100 mg twice daily. A total daily dose of 200 mg has been shown to be equally effective whether administered as 100 mg twice daily or 200 mg once daily.

14.4 Ankylosing Spondylitis

In the PreSAP trial, the hazard ratio for this same composite endpoint (adjudicated) was 1.2 (95% CI 0.6 - 2.4) with CELEBREX 400 mg once daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 2.3% (21/933 subjects) and 1.9% (12/628 subjects), respectively.

Clinical trials of other COX-2 selective and non-selective NSAIDs of up to three-years duration have shown an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. As a result, all NSAIDs are considered potentially associated with this risk.

14.5 Analgesia, including Primary Dysmenorrhea

In the APF trial, the hazard ratios compared to placebo for a composite endpoint (adjudicated) of cardiovascular death, myocardial infarction, or stroke were 3.4 (95% CI 1.4 - 8.5) with celecoxib 400 mg twice daily and 2.8 (95% CI 1.1 - 7.2) with celecoxib 200 mg twice daily. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects), respectively, compared to placebo (0.3% subjects) with placebo group. In the increases in both celecoxib dose groups versus placebo-treated patients were mainly due to an increased incidence of myocardial infarction.

In the PreSAP trial, the hazard ratio for this same composite endpoint (adjudicated) was 1.2 (95% CI 0.6 - 2.4) with CELEBREX 400 mg once daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 2.3% (21/933 subjects) and 1.9% (12/628 subjects), respectively.

Clinical trials of other COX-2 selective and non-selective NSAIDs of up to three-years duration have shown an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. As a result, all NSAIDs are considered potentially associated with this risk.

14.6 Special Studies

14.6.1 Adenomatous Polyp Prevention Studies

CELEBREX was evaluated in AS patients in two placebo- and active-controlled clinical trials of 6 and 12 weeks duration. CELEBREX at doses of 100 mg twice daily, 200 mg once daily and 400 mg once daily was shown to be statistically superior to placebo in these measures. In the PreSAP trial, the hazard ratio for this same composite endpoint (adjudicated) was 1.2 (95% CI 0.6 - 2.4) with CELEBREX 400 mg once daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 2.3% (21/933 subjects) and 1.9% (12/628 subjects), respectively.

Clinical trials of other COX-2 selective and non-selective NSAIDs of up to three-years duration have shown an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. As a result, all NSAIDs are considered potentially associated with this risk.

CELEBREX Long-Term Arthritis Safety Study (CLASS): This was a prospective, long-term, safety outcome study conducted post-marketing in approximately 5,800 OA patients and 2,200 RA patients. Patients received CELEBREX 400 mg twice daily (4-fold and 2-fold the recommended OA and RA doses, respectively). Ibuprofen 800 mg three times daily or diclofenac 75 mg twice daily (common therapeu- tic doses). Median exposures for CELEBREX (n = 3,397) and diclofenac (n = 1,996) were 9 months while ibuprofen (n = 1,985) was 6 months. The primary endpoint of this outcome study was the incidence of complicated ulcers (gastrointestinal bleeding, perforation or obstruction). Patients were allowed to take concomitant low-dose (≤ 325 mg/day) aspirin (ASA) for cardiovascular prophylaxis (ASA subgroups: CELEBREX: n = 882; diclofenac, n = 445; ibuprofen, n = 412). Differences in the incidence of complicated ulcers between CELEBREX and the combined group of ibuprofen and diclofenac were not statistically significant.

Patients on CELEBREX and concomitant low-dose ASA (n=882) experienced 4-fold higher rates of complicated ulcers compared to those on placebo (n=3,106). The Kaplan-Meier rate for complicated ulcers at 9 months was 1.12% versus 0.32% for those on low-dose ASA and those not on ASA, respectively [see Warnings and Precautions (5.4)]. The estimated cumulative rates at 9 months of complicated and symptomatic ulcers for patients treated with CELEBREX 400 mg twice daily are described in Table 4. Table 4 also displays results for patients less than or greater than 65 years of age. The difference in rates between CELEBREX alone and CELEBREX with ASA groups may be due to the higher risk for GI events in ASA users.

Table 4: Complicated and Symptomatic Ulcer Rates in Patients Taking CELEBREX 400 mg Twice Daily (Kaplan-Meier Rates at 9 months [%]) Based on Risk Factors

| All Patients | CELEBREX alone (n=3105) | 0.78 |
| CELEBREX with ASA (n=882) | 2.19 |
| Patients <65 Years | CELEBREX alone (n=2025) | 0.47 |
| CELEBREX with ASA (n=403) | 1.26 |
| Patients ≥65 Years | CELEBREX alone (n=1080) | 1.40 |
| CELEBREX with ASA (n=479) | 3.06 |

In a small number of patients with a history of ulcer disease, the complicated and symptomatic ulcer rates in patients taking CELEBREX alone or CELEBREX with ASA were, respectively, 2.56% (n=243) and 6.83% (n=91) at 48 weeks. These results are to be expected in patients with a prior history of ulcer disease [see Warnings and Precautions (5.4) and Adverse Reactions (6.1)].

Cardiovascular safety outcomes were also evaluated in the CLASS trial. Kaplan-Meier cumulative rates for investigator-reported serious cardiovascular thromboembolic adverse events (including MI, pulmonary embolism, deep venous thrombosis, unstable angina, transient ischemic attacks, and ischemic cerebrovascular accidents) demonstrated no differences between the CELEBREX, diclofenac, or ibuprofen treatment groups. The cumulative rates in all patients at nine months for CELEBREX, diclofenac, and ibuprofen were 1.2%, 1.4%, and 1.1%, respectively. The cumulative rates in non-ASA users at nine months in each of the three treatment groups were less than 1%. The cumulative rates for myocardial infarction in non-ASA users at nine months in each of the three treatment groups were less than 0.5%. The Kaplan-Meier rate for complicated ulcers at 9 months was 1.12% versus 0.32% for those on low-dose ASA and those not on ASA, respectively [see Warnings and Precautions (5.4)].

Endoscopic Studies: The correlation between findings of short-term endoscopic studies with CELEBREX and the relative incidence of clinically significant serious upper GI events with long-term use has not been established. Serious clinically significant upper GI bleeding has been observed in patients receiving CELEBREX in controlled and open-labeled trials [see Warnings and Precautions (5.4) and Clinical Studies (14.6)].

A randomized, double-blind study in 430 RA patients was conducted in which an endo- scopic examination was performed at 6 months. The incidence of endoscopic ulcers in patients taking CELEBREX 200 mg twice daily was 4% vs. 15% for patients taking diclofenac SR 75 mg twice daily. However, CELEBREX was not statistically different than diclofenac for clinically relevant GI outcomes in the CLASS trial [see Clinical Studies (14.6)].

The incidence of endoscopic ulcers was studied in two 12-week, placebo-controlled studies in 2157 OA and RA patients in whom baseline endoscopy revealed no ulcers. There was no dose relationship for the incidence of gastroduodenal ulcers and the dose of CELEBREX (50 mg to 400 mg twice daily). The incidence for naproxen 500 mg twice daily...
daily was 16.2 and 17.6% in the two studies, for placebo was 2.0 and 2.3%, and for all doses of COLEBREX the incidence ranged between 2.7%-5.9%. There have been no large, clinical outcome studies to compare clinically relevant GI outcomes with COLEBREX and naproxen.

In the endoscopic studies, approximately 11% of patients were taking aspirin (≥325 mg/day). In the COLEBREX groups, the endoscopic ulcer rate appeared to be higher in aspirin users than in non-users. However, the increased rate of ulcers in these aspirin users was less than the endoscopic ulcer rates observed in the active comparator groups, with or without aspirin.

16. HOW SUPPLIED/STORAGE AND HANDLING

COLEBREX 50 mg capsules are white, with reverse printed white on red band of box and cap with markings of 7767 on the cap and 50 on the body, supplied as:

<table>
<thead>
<tr>
<th>NDC Number</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>0025-1515-01</td>
<td>bottle of 60</td>
</tr>
</tbody>
</table>

COLEBREX 100 mg capsules are white, with reverse printed white on blue band of box and cap with markings of 7767 on the cap and 100 on the body, supplied as:

<table>
<thead>
<tr>
<th>NDC Number</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>0025-1520-31</td>
<td>bottle of 100</td>
</tr>
<tr>
<td>0025-1520-51</td>
<td>bottle of 500</td>
</tr>
<tr>
<td>0025-1520-34</td>
<td>carton of 100 unit dose</td>
</tr>
</tbody>
</table>

COLEBREX 200 mg capsules are white, with reverse printed white on gold band with markings of 7767 on the cap and 200 on the body, supplied as:

<table>
<thead>
<tr>
<th>NDC Number</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>0025-1525-31</td>
<td>bottle of 100</td>
</tr>
<tr>
<td>0025-1525-51</td>
<td>bottle of 500</td>
</tr>
<tr>
<td>0025-1525-34</td>
<td>carton of 100 unit dose</td>
</tr>
</tbody>
</table>

COLEBREX 400 mg capsules are white, with reverse printed white on green band with markings of 7767 on the cap and 400 on the body, supplied as:

<table>
<thead>
<tr>
<th>NDC Number</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>0025-1530-02</td>
<td>bottle of 60</td>
</tr>
<tr>
<td>0025-1530-01</td>
<td>carton of 100 unit dose</td>
</tr>
</tbody>
</table>

Storage: Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]

17. PATIENT COUNSELING INFORMATION

Patients should be informed of the following information before initiating therapy with COLEBREX and periodically during the course of ongoing therapy.

17.1 Medication Guide

Patients should be informed of the availability of a Medication Guide for NSAIDs that accompanies each prescription dispensed, and should be instructed to read the Medication Guide prior to using COLEBREX.

17.2 Cardiovascular Effects

Patients should be informed that COLEBREX may cause serious CV side effects such as MI or stroke, which may result in hospitalization and even death. Patients should be informed of the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and to seek immediate medical advice if they observe any of these signs or symptoms. [see Warnings and Precautions (5.1)].

Patients should be informed that COLEBREX can lead to the onset of new hypertension or worsening of preexisting hypertension, and that COLEBREX may impair the response of some antihypertensive agents. Patients should be instructed on the proper follow up for monitoring of blood pressure. [see Warnings and Precautions (5.2) and Drug Interactions (7.4)].

17.3 Gastrointestinal Effects

Patients should be informed that COLEBREX can cause gastrointestinal discomfort and more serious side effects, such as ulcers and bleeding, which may result in hospitalization and even death. Patients should be informed of the signs and symptoms of ulcerations and bleeding, and to seek immediate medical advice if they observe any signs or symptoms that are indicative of these disorders, including epigastric pain, dyspepsia, melena, and hematemesis. [see Warnings and Precautions (5.4)].

17.4 Hepatic Effects

Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and “flu-like” symptoms). Patients should be instructed that they should stop therapy and seek immediate medical treatment if these signs and symptoms occur [see Warnings and Precautions (5.5), Use in Specific Populations (8.6)].

17.5 Adverse Skin Reactions

Patients should be informed that COLEBREX is a sulfonamide and can cause serious skin side effects such as exfoliative dermatitis, SJS, and TEN, which may result in hospitalizations and even death. Although serious skin reactions may occur without warning, patients should be informed of the signs and symptoms of skin rash and blisters, fever, or other signs of hypersensitivity such as itching, and seek immediate medical advice when observing any indicative signs or symptoms.

Patients should be advised to stop COLEBREX immediately if they develop any type of rash and contact their physician as soon as possible.

Patients with prior history of sulfa allergy should not take COLEBREX [see Warnings and Precautions (5.8)].

17.6 Weight Gain and Edema

Long-term administration of NSAIDs including COLEBREX has resulted in renal injury. Patients at greatest risk are those taking diuretics, ACE-inhibitors, angiotensin II antagonists, or with renal or liver dysfunction, heart failure, and the elderly [see Warnings and Precautions (5.3, 5.6), Use in Specific Populations (8)].

Patients should be instructed to promptly report to their physicians signs or symptoms of unexplained weight gain or edema following treatment with COLEBREX [see Warnings and Precautions (5.3)].

17.7 Anaphylactoid Reactions

Patients should be informed of the signs and symptoms of an anaphylactoid reaction (e.g., difficulty breathing, swelling of the face or throat). Patients should be instructed to seek immediate emergency assistance if they develop any of these signs and symptoms [see Warnings and Precautions (5.7)].

17.8 Effects During Pregnancy

Patients should be informed that in late pregnancy COLEBREX should be avoided because it may cause premature closure of the ductus arteriosus [see Warnings and Precautions (5.9), Use in Specific Populations (8.1)].

17.9 Preexisting Asthma

Patients should be instructed to tell their physicians if they have a history of asthma or aspirin-sensitive asthma because the use of NSAIDs in patients with aspirin-sensitive asthma has been associated with severe bronchospasm, which can be fatal. Patients with this form of aspirin sensitivity should be instructed not to take COLEBREX. Patients with preexisting asthma should be instructed to seek immediate medical attention if their asthma worsens after taking COLEBREX [see Warnings and Precautions (5.13)].
NSAID medicines should only be used:
- exactly as prescribed
- at the lowest dose possible for your treatment
- for the shortest time needed

What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?
NSAID medicines are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as:
- different types of arthritis
- menstrual cramps and other types of short-term pain

Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?
Do not take an NSAID medicine:
- if you had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAID medicine
- for pain relief before or after heart bypass surgery

Tell your healthcare provider:
- about all of your medical conditions.
- about all of the medicines you take. NSAIDs and some other medicines can interact with each other and cause serious side effects. Keep a list of your medicines to show to your healthcare provider and pharmacist.
- if you are pregnant. NSAID medicines should not be used by pregnant women late in their pregnancy.
- if you are breastfeeding. Talk to your doctor.

What are the possible side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?

### Serious side effects include:
- heart attack
- stroke
- high blood pressure
- heart failure from body swelling (fluid retention)
- kidney problems including kidney failure
- bleeding and ulcers in the stomach and intestine
- low red blood cells (anemia)
- life-threatening skin reactions
- life-threatening allergic reactions
- liver problems including liver failure
- asthma attacks in people who have asthma

### Other side effects include:
- stomach pain
- constipation
- diarrhea
- gas
- heartburn
- nausea
- vomiting
- dizziness

Get emergency help right away if you have any of the following symptoms:
- shortness of breath or trouble breathing
- chest pain
- weakness in one part or side of your body
- slurred speech
- swelling of the face or throat

Stop your NSAID medicine and call your healthcare provider right away if you have any of the following symptoms:
- nausea
- more tired or weaker than usual
- itching
- your skin or eyes look yellow
- stomach pain
- flu-like symptoms
- vomit blood
- there is blood in your bowel movement or it is black and sticky like tar
- skin rash or blisters with fever
- unusual weight gain
- swelling of the arms and legs, hands and feet

These are not all the side effects with NSAID medicines. Talk to your healthcare provider or pharmacist for more information about NSAID medicines.

### Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Aspirin is an NSAID medicine but it does not increase the chance of a heart attack. Aspirin can cause bleeding in the brain, stomach, and intestines. Aspirin can also cause ulcers in the stomach and intestines.
- Some of these NSAID medicines are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.

### NSAID medicines that need a prescription

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Tradename</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celecoxib</td>
<td>Celebrex</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>Cataflam, Voltaren, Arthrotec (combined with misoprostol)</td>
</tr>
<tr>
<td>Diflunisal</td>
<td>Dolobid</td>
</tr>
<tr>
<td>Etodolac</td>
<td>Lodine, Lodine XL</td>
</tr>
<tr>
<td>Fenoprofen</td>
<td>Nalfon, Nalfon 200</td>
</tr>
<tr>
<td>Flurbiprofen</td>
<td>Ansaid</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>Motrin, Tab-Profen, Vicoprofen* (combined with hydrocodone), Comburpin (combined with oxycodone)</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>Indocin, Indocin SR, Indo-Lemmon, Indomethagan</td>
</tr>
<tr>
<td>Ketoprofen</td>
<td>Oruvail</td>
</tr>
<tr>
<td>Ketorolac</td>
<td>Toradol</td>
</tr>
<tr>
<td>Mefenamic Acid</td>
<td>Ponstel</td>
</tr>
<tr>
<td>Meloxicam</td>
<td>Mobic</td>
</tr>
<tr>
<td>Nabumetone</td>
<td>Relafen</td>
</tr>
<tr>
<td>Naproxen</td>
<td>Naprosyn, Anaprox, Anaprox DS, EC-Naproxyn, Naprelan, Naprapac (copackaged with lansoprazole)</td>
</tr>
<tr>
<td>Oxaprozin</td>
<td>Daypro</td>
</tr>
<tr>
<td>Piroxicam</td>
<td>Feldene</td>
</tr>
<tr>
<td>Sulindac</td>
<td>Clinoril</td>
</tr>
<tr>
<td>Tolmetin</td>
<td>Tolectin, Tolectin DS, Tolectin 600</td>
</tr>
</tbody>
</table>

* Vicoprofen contains the same dose of ibuprofen as over-the-counter (OTC) NSAIDs, and is usually used for less than 10 days to treat pain. The OTC NSAID label warns that long term continuous use may increase the risk of heart attack or stroke.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

LAB-0609-1.0